Prescription drug affordability is a growing concern worldwide, and both Australia and Canada have systems in place to help manage the rising cost of medications. While both countries prioritize public access to essential drugs, they approach drug pricing control in different ways. Understanding these differences offers insight into the strengths and challenges of each nation’s healthcare system when it comes to prescription medications.
Australia: The Pharmaceutical Benefits Scheme (PBS)
Australia controls prescription drug prices through its Pharmaceutical Benefits Scheme (PBS), a national program introduced in 1948. The PBS ensures that essential medications are accessible at affordable prices for all Australians. Here’s how it works:
- The government negotiates directly with pharmaceutical companies to set prices for medications that are listed on the PBS.
- Once a drug is approved and added to the PBS, the government subsidizes the majority of the cost, significantly reducing the price for consumers.
- As of 2025, Australians pay a maximum of AUD $31.60 per prescription, while concession cardholders pay around AUD $7.70.
- The PBS Safety Net protects individuals and families from high cumulative prescription costs. After reaching a certain threshold, patients pay even less for their medicines for the rest of the year.
This system allows Australians to access high-cost medications without financial strain. The Pharmaceutical Benefits Advisory Committee (PBAC) rigorously evaluates each medication for clinical effectiveness, cost-efficiency, and public need before it’s added to the PBS, ensuring taxpayer funds are used wisely.
Canada: Provincial Plans and Price Regulation
Unlike Australia, Canada does not have a single national drug pricing program like the PBS. Instead, Canada manages prescription drug costs through a combination of provincial drug plans, private insurance, and federal price regulation.
Patented Medicine Prices Review Board (PMPRB)
Canada’s Patented Medicine Prices Review Board (PMPRB) plays a key role in controlling drug prices. It sets a maximum allowable price for patented (brand-name) drugs by comparing Canadian prices to those in other countries. However, the PMPRB does not negotiate prices directly with pharmaceutical companies, nor does it control prices for generic medications.
Public Drug Plans
Each province and territory in Canada offers its own public drug plan, usually focused on specific groups like:
- Seniors
- Low-income residents
- People with chronic conditions
Most Canadians, however, rely on private health insurance through employers to cover prescription costs, or they pay out of pocket. This leads to variability in drug access and affordability, depending on where you live and your employment status.
Challenges and Comparisons
Australia’s PBS model offers consistency and nationwide affordability, making it easier for patients to predict their medication costs. Canada’s provincial system is more fragmented, leading to uneven access and higher out-of-pocket expenses for many people.
Additionally, Australia has more leverage to negotiate lower prices directly with pharmaceutical companies, while Canada’s pricing control is primarily regulatory and reactive rather than proactive.
Conclusion
Both Australia and Canada are committed to making prescription drugs affordable, but they take different paths to achieve this goal. Australia’s centralized PBS system ensures predictable costs and broader access, while Canada’s mixed model of public plans, private insurance, and federal oversight creates a more complex landscape. As both countries face rising healthcare costs, the Australian approach may offer valuable lessons for Canadian policymakers considering national pharmacare reform.